In addition, all treatments were able to decrease the arthritis score by almost half (with significant changes being observed after 20 days of treatment) and to downregulate serum levels of IL-1β, TNF-α, IL-6, and IFN-γ (also in a dose-dependent manner, with the high dose being comparable to dexamethasone in some cases (p < 0.01)). This evidence concerns the gene IL6 and arthritic joint disease.